HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine

AIDS

Volumn 25, Issue 12, 2011, Pages 1461-1469

  Hunt, Gillian M ^a   Coovadia, Ashraf ^b   Abrams, Elaine J ^c   Sherman, Gayle ^b   Meyers, Tammy ^d   Morris, Lynn ^a   Kuhn, Louise ^e  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c Columbia University ^*  (United States)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

Author keywords

antiretroviral therapy initiation; HIV 1 drug resistance; infants and young children; single dose nevirapine

Indexed keywords

LOPINAVIR PLUS RITONAVIR; NEVIRAPINE;

ANTIVIRAL THERAPY; ARTICLE; CHILD; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; SOUTH AFRICA; VIRUS TRANSMISSION;

DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; NEVIRAPINE; POLYMERASE CHAIN REACTION; PREVALENCE; RNA, VIRAL; SOUTH AFRICA; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79960561280     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283492180     Document Type: Article

References (38)

1. Fowler MG, Lampe MA, Jamieson DJ, Kourtis AP, Rogers MF. Reducing the risk of mother-to-child human immunodeficiency virus transmission: past successes, current progress and challenges, and future directions. Am J Obstet Gynecol 2007; 197:S3-9. (Pubitemid 47354193)
2. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951-1957. (Pubitemid 32980636)
3. Johnson JA, Li JF, Morris L, Martinson N, Gray G, McIntyre J, Heneine W. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192:16-23. (Pubitemid 40863852)
4. Kuhn L, Sinkala M, Kankasa MP, Kasonde P, Thea DM, Aldrovandi GM. Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission. J Acquir Immune Defic Syndr 2006; 42:260-262. (Pubitemid 43884726)
5. Flys TS, Mwatha A, Guay LA, Nakabiito C, Donnell D, Musoke P, et al. Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine. AIDS 2007; 21:2077-2082. (Pubitemid 47462157)
6. Kassaye S, Lee E, Kantor R, Johnston E, Winters M, Zijenah L, et al. Drug resistance in plasma and breast milk after singledose nevirapine in subtype C HIV type 1: population and clonal sequence analysis. AIDS Res Hum Retroviruses 2007; 23:1055-1061. (Pubitemid 47492348)
7. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006; 20:995-1002.
8. Flys TS, McConnell MS, Matovu F, Church JD, Bagenda D, Khaki L, et al. Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission. J Infect Dis 2008; 198:465-469.
9. Martinson NA, Morris L, Gray G, Moodley D, Pillay V, Cohen S, et al. Selection and persistence of viral resistance in HIVinfected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007; 44:148-153. (Pubitemid 46292216)
10. Kurle SN, Gangakhedkar RR, Sen S, Hayatnagarkar SS, Tripathy SP, Paranjape RS. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India. AIDS Res Hum Retroviruses 2007; 23:682-685. (Pubitemid 46867465)
11. Church JD, Omer SB, Guay LA, Huang W, Lidstrom J, Musoke P, et al. Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis 2008; 198:1075-1082.
12. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-1021. (Pubitemid 350018545)
13. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005; 19:2167-2169. (Pubitemid 41669007)
14. Troyer RM, Lalonde MS, Fraundorf E, Demers KR, Kyeyune F, Mugyenyi P, et al. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. AIDS Res Hum Retroviruses 2008; 24:235-250. (Pubitemid 351282099)
15. Micek MA, Blanco AJ, Beck IA, Dross S, Matunha L, Montoya P, et al. Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine. Clin Infect Dis 2010; 50:1405-1414.
16. MacLeod IJ, Rowley CF, Thior I, Wester C, Makhema J, Essex M, Lockman S. Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART. J Clin Virol 2010; 48:162-167.
17. Rowley CF, Boutwell CL, Lee EJ, MacLeod IJ, Ribaudo HJ, Essex M, Lockman S. Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. AIDS Res Hum Retroviruses 2010; 26:293-300.
18. Palmer S, Boltz V, Martinson N, Maldarelli F, Gray G, McIntyre J, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 2006; 103:7094-7099.
19. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 2007; 17:1195-1201. (Pubitemid 47204863)
20. Moorthy A, Kuhn L, Coovadia A, Meyers T, Strehlau R, Sherman G, et al. Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. Clin Infect Dis 2010; 52:514-521.
21. Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA 2010; 304:1082-1090.
22. Pillay V, Ledwaba J, Hunt G, Rakgotho M, Singh B, Makubalo L, et al. Antiretroviral drug resistance surveillance among drugnaive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13 (Suppl 2):101-107. (Pubitemid 352019096)
23. Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 2009; 48:462-472.
24. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17:138-145.
25. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363: 1510-1520.
26. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach (2010 Version). http://www.who.int/hiv/pub/mtct/ antiretroviral2010/en/index. html [Accessed 16 April 2010].
27. Reitz C, Coovadia A, Ko S, Meyers T, Strehlau R, Sherman G, et al. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis. J Infect Dis 2010; 201:1121-1131.
28. Taylor BS, Hunt G, Abrams EJ, Coovadia A, Meyers T, Sherman G, et al. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses 2011; 27: (in press).
29. Church JD, Jones D, Flys T, Hoover D, Marlowe N, Chen S, et al. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn 2006; 8:430-432; quiz 527. (Pubitemid 44377924)
30. Johnson JA, Li JF, Wei X, Lipscomb J, Bennett D, Brant A, et al. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS One 2007; 2:e638.
31. Halvas EK, Wiegand A, Boltz VF, Kearney M, Nissley D, Wantman M, et al. Low frequency nonnucleoside reversetranscriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis 2010; 201:672-680.
32. Karchava M, Pulver W, Smith L, Philpott S, Sullivan TJ, Wethers J, Parker MM. Prevalence of drug-resistance mutations and nonsubtype B strains among HIV-infected infants from New York State. J Acquir Immune Defic Syndr 2006; 42:614-619. (Pubitemid 44162433)
33. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147. (Pubitemid 46089674)
34. Kuhn L, Semrau K, Ramachandran S, Sinkala M, Scott N, Kasonde P, et al. Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia. J Acquir Immune Defic Syndr 2009; 52:132-136.
35. Lockman S, Team AOS. Lopinavir/ritonavirRtenofovir/emtri citabine is superior to nevirapineRtenofovir/emtracitabine for women with prior exposure to single-dose nevirapine. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada; 8-11 February 2009.
36. Stringer JS, McConnell MS, Kiarie J, Bolu O, Anekthananon T, Jariyasethpong T, et al. Effectiveness of nonnucleoside reversetranscriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multicountry, prospective cohort study. PLoS Med 2010; 7:e1000233.
37. Musoke PM, Barlow-Mosha L, Bagenda D, Mudiope P, Mubiru M, Ajuna P, et al. Response to antiretroviral therapy in HIVinfected Ugandan children exposed and not exposed to singledose nevirapine at birth. J Acquir Immune Defic Syndr 2009; 52:560-568.
38. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIVinfected infants. N Engl J Med 2008; 359:2233-2244.